# Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

> **NCT05061550** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 630 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Oleclumab
- **DRUG:** Monalizumab
- **DRUG:** Dato-DXd
- **DRUG:** AZD0171
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed/Cisplatin
- **DRUG:** Pemetrexed/Carboplatin
- **DRUG:** Carboplatin/Paclitaxel
- **DRUG:** Volrustomig
- **DRUG:** Rilvegostomig

## Key facts

- **NCT ID:** NCT05061550
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-14
- **Primary completion:** 2030-05-28
- **Final completion:** 2030-05-28
- **Target enrollment:** 630 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061550, "Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05061550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*